Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025

Regeneron Pharmaceuticals, Inc. ( REGN ) share price has fallen 22.5% over the past six months, reflecting Wall Street concerns about the prospects of its Eylea franchise in the short term due to increased competition from itsWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, ...